Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript

Agios Pharmaceuticals, Inc. ( AGIO ) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia December 24, 2025 8:00 AM EST Company Participants Morgan Sanford - Vice President of Investor Relations Brian Goff - CEO & Director Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Gregory Renza - Truist Securities, Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Alec Stranahan - BofA Securities, Research Division Marc Frahm - TD Cowen, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Jiayi Yuan - RBC Capital Markets, Research Division Presentation Operator Good day, and welcome to Agios Pharmaceuticals' Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios. Morgan Sanford Vice President of Investor Relations Thank you, operator. Good morning, everyone. Thank you for joining us to discuss the FDA approval of mitapivat for the treatment of anemia in adults with alpha or beta thalassemia which will be marketed under the brand name AQVESME in the United States. You can access the slides for today's call by going to the Investors section of our website, agios.com. Next slide, please. Please note, we'll be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements due to various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the next slide, you'll find the agenda for today's call. On the call with

Preview: ~312 words